Financial Performance - The company's revenue for Q3 2022 was ¥93,694,824.33, a decrease of 37.84% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥26,525,648.05, down 40.84% year-on-year[5]. - The basic earnings per share decreased by 55.63% to ¥0.1236[5]. - Total operating revenue for the current period is ¥340,063,752.73, a decrease of 11.8% from ¥385,680,466.47 in the previous period[18]. - Net profit for the current period is ¥95,774,963.98, up 1.3% from ¥94,506,633.28 in the previous period[19]. - Basic and diluted earnings per share decreased to ¥0.4462 from ¥0.5871, a decline of 24%[19]. - The company reported a total profit of ¥113,084,904.68, slightly up from ¥112,101,896.21 in the previous period[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,279,355,347.64, an increase of 2.65% from the end of the previous year[5]. - As of September 30, 2022, the total assets of Jiujiang Shanshui Technology Co., Ltd. amounted to CNY 2,279,355,347.64, an increase from CNY 2,220,602,138.72 at the beginning of the year[15]. - The company's total liabilities decreased to CNY 240,289,758.87 from CNY 245,976,239.79[16]. - The total equity attributable to shareholders increased to CNY 2,039,065,588.77 from CNY 1,974,625,898.93[16]. - Cash and cash equivalents as of September 30, 2022, were CNY 1,433,581,324.19, down from CNY 1,518,296,935.82 at the beginning of the year[15]. - The total current assets decreased to CNY 2,042,257,439.45 from CNY 2,073,669,340.94[15]. Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥94,398,155.82, a decrease of 2.77%[5]. - Cash flow from operating activities generated a net amount of ¥94,398,155.82, down from ¥97,086,046.48 in the previous period[20]. - Cash inflow from investment activities totaled ¥384,404,095.85, compared to ¥216,821,561.81 in the previous period, indicating a significant increase[20]. - Cash outflow from investment activities rose sharply to ¥1,032,420,401.96 from ¥237,921,526.06, resulting in a net cash flow from investment activities of -¥648,016,306.11[20]. - Cash and cash equivalents at the end of the period decreased to ¥920,139,518.63 from ¥1,518,296,935.82, reflecting a decline of 39.5%[21]. Expenses and Costs - Sales expenses increased by 82.96% to ¥1,549,518.98, attributed to intensified market expansion efforts[9]. - Total operating costs decreased to ¥245,265,508.64 from ¥278,134,274.75, reflecting a reduction of 11.8%[18]. Other Financial Metrics - The company recorded a 6005.56% increase in non-operating income, amounting to ¥13,667,399.32, primarily from government subsidies[10]. - The company’s weighted average return on equity decreased by 14.32% to 4.77% year-to-date[5]. - The company has not disclosed any new product developments or market expansion strategies in the current report[17]. - The company did not conduct an audit for the third quarter report[22]. Inventory and Receivables - Accounts receivable decreased significantly to CNY 1,487,179.38 from CNY 4,360,341.63[15]. - The company's inventory increased to CNY 91,956,963.18 from CNY 83,664,110.02[15]. - The company reported a significant increase in prepayments to CNY 10,314,750.24 from CNY 5,053,051.48[15]. Construction and Projects - The company reported a significant increase in construction in progress, rising by 2599.16% to ¥64,464,391.23 due to project completion progress[9].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 246,368,928.40, representing a 4.86% increase compared to CNY 234,950,502.83 in the same period last year[30]. - The net profit attributable to shareholders was CNY 69,249,315.93, a significant increase of 39.42% from CNY 49,668,957.69 year-on-year[30]. - The net cash flow from operating activities reached CNY 91,486,382.80, marking a 72.86% increase compared to CNY 52,924,172.58 in the previous year[30]. - The basic earnings per share rose to CNY 0.3226, up 4.57% from CNY 0.3085 in the same period last year[30]. - The company reported a net profit after deducting non-recurring gains and losses of CNY 58,262,539.93, which is a 24.28% increase from CNY 46,878,245.94 year-on-year[30]. - The company's operating costs decreased by 3.17%, amounting to CNY 149,407,658.98, down from CNY 154,302,958.50 in the previous year[56]. - The company achieved a significant increase in cash flow from operating activities, which rose by 72.86% to CNY 91,486,382.80, attributed to higher sales revenue and cash received from services[56]. - The company reported a significant increase in non-operating income, which rose by 4,446.93% to CNY 10,150,200.32, primarily due to government subsidies received during the reporting period[57]. Market and Competitive Position - The company is engaged in the research, production, and sales of dye intermediates, pesticides, and pharmaceutical intermediates, indicating a focus on the fine chemical industry[38]. - The fine chemical market is expected to maintain a high growth trend due to increasing demand for new materials and sustainable development practices[38]. - The core product 6-nitro compound has a market capacity of approximately 35,000 tons, with the company holding a market share of about 30%[46]. - The average selling price of related products during the reporting period was higher than the same period last year, contributing to the revenue growth despite the pandemic's impact[45]. - The company's market share in the dye intermediate sector remains strong, maintaining a leading position due to stable product quality and excellent customer service[52]. Research and Development - The company has developed a core technology system for products like 6-nitro and 5-nitro intermediates, but must keep pace with market demands to maintain its competitive edge[9]. - The company has implemented measures to protect its intellectual property, but risks of technology leakage still exist, which could harm business performance[10]. - The company has developed three core technology platforms that enhance product quality while reducing costs, leading to a competitive advantage in niche markets[44]. - Research and development expenses increased by 37.84% to CNY 10,762,741.73, driven by increased costs associated with university-enterprise cooperation projects[56]. - The company is focused on R&D in fine chemicals, particularly in 6-nitro and 5-nitro products[82]. Environmental and Safety Measures - The company emphasizes environmental protection and has invested in facilities to manage waste, but increasing environmental regulations may raise costs and affect performance[6]. - The company has implemented a comprehensive hazardous waste management plan, with a total of 389.8 tons of waste processed[94]. - The wastewater treatment plant achieved a chemical oxygen demand (COD) concentration of 58.5 mg/L, well below the standard limit of 500 mg/L[94]. - The company has established wastewater treatment facilities and air pollution control facilities, all operating normally to ensure compliance with pollutant discharge standards[99]. - The company has established a self-built wastewater treatment facility at the Qishan Industrial Park, ensuring compliance with environmental regulations[94]. - The company has taken measures to reduce carbon emissions, including energy-saving training for employees and implementing energy-saving modifications, resulting in reduced energy consumption and lower pollutant emissions[106]. - The company has established a dedicated safety and environmental protection department to oversee compliance with safety production laws and regulations[109]. - The company has implemented a standardized safety production management system and has passed the ISO 45001:2018 certification[110]. Corporate Governance and Shareholder Matters - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[11]. - The company held its first extraordinary general meeting of 2022 on February 18, with an investor participation ratio of 58.97%[87]. - The company appointed a new independent director, Wang Zhigang, on March 25, 2022, following the resignation of Yi Youru[89]. - The company did not implement any equity incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period[91]. - The total number of shares before the change was 163,744,913, with a post-change total of 160,976,500, reflecting a decrease of 2,768,413 shares[137]. - The overall shareholding structure remains stable, with no new major shareholders entering the market[138]. - The total number of common shareholders at the end of the reporting period is 23,092[142]. - The largest shareholder, Huang Guorong, holds 18.64% of the shares, amounting to 40,000,000 shares[142]. Operational Challenges - The ongoing COVID-19 pandemic presents uncertainties for the company's operations, potentially affecting production and logistics[8]. - The company has faced price fluctuations in its dye intermediates, pesticides, and pharmaceutical intermediates due to raw material costs and market competition, impacting revenue significantly if adverse changes occur[4]. - The company aims to strengthen its core competitiveness in response to external challenges such as the COVID-19 pandemic and the Russia-Ukraine conflict[38]. - The company is actively managing risks related to COVID-19 that may affect operations and supply chains[81]. Financial Position and Assets - Total assets at the end of the reporting period were CNY 2,266,559,258.10, reflecting a 2.07% increase from CNY 2,220,602,138.72 at the end of the previous year[30]. - The total liabilities increased to CNY 254,329,668.69 from CNY 245,976,239.79, reflecting a growth of about 3.5%[157]. - The company's equity attributable to shareholders reached CNY 2,012,229,589.41, up from CNY 1,974,625,898.93, indicating an increase of approximately 1.9%[157]. - The total amount of funds raised was ¥1,383.97 million, with ¥3.15 million invested during the reporting period[65]. - The company has committed to a project with a total investment of ¥126.03 million, which is expected to be completed by December 31, 2023[67].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 103,544,759.81, representing a 19.41% increase compared to CNY 86,710,208.54 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 24,222,495.37, an increase of 80.23% from CNY 13,440,086.80 year-on-year[3] - The net profit after deducting non-recurring gains and losses was CNY 23,823,152.49, up 94.98% from CNY 12,217,962.64 in the previous year[3] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.1129, reflecting a 35.21% increase from CNY 0.0835 in the previous year[3] - The net profit for the first quarter was CNY 24,222,495.37, representing a significant increase of 80.1% compared to CNY 13,440,086.80 in the previous year[17] - The net profit attributable to the parent company for Q1 2022 was ¥24,222,495.37, an increase from ¥13,440,086.80 in Q1 2021, representing an increase of approximately 80.5%[18] Cash Flow - The net cash flow from operating activities reached CNY 57,870,395.73, a significant increase of 767.74% compared to CNY 6,669,105.19 in the same quarter last year[3] - Cash inflow from operating activities for Q1 2022 was ¥87,937,683.66, significantly higher than ¥35,480,895.52 in Q1 2021, marking an increase of approximately 147.5%[20] - The net cash flow from operating activities for Q1 2022 was ¥57,870,395.73, compared to ¥6,669,105.19 in Q1 2021, indicating a substantial increase of approximately 767.5%[20] - The total cash and cash equivalents at the end of Q1 2022 amounted to ¥1,524,817,313.94, compared to ¥29,683,273.23 at the end of Q1 2021, showing a significant increase[22] - The company reported cash received from sales of goods and services of ¥85,270,513.76 in Q1 2022, up from ¥35,097,656.27 in Q1 2021, an increase of approximately 142.6%[20] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 2,192,653,909.32, a decrease of 1.26% from CNY 2,220,602,138.72 at the end of the previous year[3] - The total current assets decreased to CNY 2,046,365,575.60 from CNY 2,073,669,340.94, indicating a reduction of 1.3%[12] - The total liabilities decreased to CNY 193,354,931.32 from CNY 245,976,239.79, showing a decline of 21.4%[14] - The company's cash and cash equivalents increased to CNY 1,524,817,313.94 from CNY 1,518,296,935.82, a growth of 0.4%[12] Shareholder Information - The company reported a total of 29,906 common shareholders at the end of the reporting period[9] - The top shareholder, Huang Guorong, holds 18.64% of the shares, amounting to 40,000,000 shares[9] - Shareholders' equity attributable to the parent company increased by 1.25% to CNY 1,999,298,978.00 from CNY 1,974,625,898.93 at the end of the previous year[3] - The company’s equity attributable to shareholders increased to CNY 1,999,298,978.00 from CNY 1,974,625,898.93, marking a rise of 1.2%[14] Expenses - The total operating costs amounted to CNY 74,139,729.39, up from CNY 71,461,885.37, reflecting a year-over-year increase of 3.7%[17] - Research and development expenses for the quarter were CNY 3,067,424.02, up from CNY 1,857,673.05, reflecting a year-over-year increase of 65.0%[17] - The company paid ¥14,450,132.94 in employee compensation during Q1 2022, compared to ¥11,897,290.69 in Q1 2021, reflecting an increase of approximately 21.5%[20] Other Financial Metrics - The significant increase in net profit was attributed to strong order demand, market recovery, and improved product profitability[7] - The company's investment cash outflow for Q1 2022 was ¥99,085,663.58, compared to ¥56,901,548.47 in Q1 2021, indicating an increase of approximately 74.0%[22] - The cash flow from investment activities in Q1 2022 resulted in a net outflow of ¥38,512,237.95, a decrease from a net inflow of ¥11,125,451.54 in Q1 2021[22] - The company reported a significant increase in accounts receivable, which rose to CNY 18,930,707.02 from CNY 4,360,341.63, indicating a growth of 334.5%[12]

Financial Performance - The company's operating revenue for 2021 was CNY 552,342,767.81, representing a 43.94% increase compared to CNY 383,744,001.43 in 2020[29]. - The net profit attributable to shareholders for 2021 was CNY 142,372,110.77, a 29.50% increase from CNY 109,937,838.32 in 2020[29]. - The net cash flow from operating activities reached CNY 101,237,512.23, marking a significant increase of 263.75% from CNY 27,831,390.63 in 2020[29]. - The total assets at the end of 2021 amounted to CNY 2,220,602,138.72, a 274.38% increase from CNY 593,140,163.45 at the end of 2020[29]. - The net assets attributable to shareholders increased by 341.37% to CNY 1,974,625,898.93 at the end of 2021, compared to CNY 447,385,387.15 at the end of 2020[29]. - The basic earnings per share for 2021 was CNY 0.8844, up 29.51% from CNY 0.6829 in 2020[29]. - The company reported a weighted average return on equity of 27.43% for 2021, slightly down from 28.02% in 2020[29]. - The fourth quarter revenue was CNY 166,662,301.34, contributing to a total annual revenue growth[31]. - The company achieved a revenue of ¥552.34 million in 2021, representing a 43.94% increase from ¥383.74 million in 2020[84]. - The net profit attributable to shareholders was ¥142.37 million, up 29.50% from ¥109.94 million in the previous year[84]. Product and Market Development - The company’s core products include dye intermediates, pesticide intermediates, and pharmaceutical intermediates, which are essential for various applications in the chemical industry[22]. - The company’s ability to adapt to technological advancements and market trends is crucial for maintaining its competitive advantage in the fine chemical sector[14]. - The company’s chlorinated pyridine series products are key intermediates for high-efficiency, low-toxicity pesticides, aligning with national environmental policies[45]. - The demand for acid dyes is expected to grow due to increased production capacity of nylon fabrics, with a 2021 production increase of 8% in nylon to 4.15 million tons[43]. - The company’s products, such as 6-nitro and oxygen intermediates, are characterized by high purity and low acidity, enhancing customer yield and reducing costs[43]. - The company is positioned to adapt to industry trends focusing on green and low-carbon development, with an emphasis on technological advancement and capacity integration[40]. - The company is actively exploring new applications for 2-chloropyridine in pharmaceuticals and daily chemicals, reflecting its adaptability to market trends[49]. - The company’s sales strategy is direct sales, with pricing influenced by product costs, market demand, and customer negotiation power[67]. - The company has formed stable partnerships with several well-known dye manufacturers, maintaining a leading market share in the dye intermediate sector[81]. Research and Development - The company has developed a core technology system through years of research and development, positioning itself at the forefront of the fine chemical industry[14]. - The company has a total of 41 R&D personnel, with 9 invention patents and 23 utility model patents, demonstrating a strong commitment to innovation[76]. - The company’s R&D expenses for the year were ¥17.99 million, reflecting an increase due to heightened investment in research and development[84]. - The company has invested 100 million RMB in R&D for new technologies aimed at improving product efficiency[156]. - The company has established a comprehensive training system for employees, including safety education and vocational qualification training[181]. Environmental and Safety Commitment - The company emphasizes its commitment to environmental protection and has implemented measures to reduce pollutant emissions, although future regulatory changes may increase environmental costs[10]. - The company has maintained a strong focus on safety production, with no major accidents reported since its establishment, but acknowledges the risks associated with handling hazardous materials[11]. - The company is committed to continuous improvement in production processes to meet increasing environmental standards and market demands[10]. - The company has established safety and environmental management systems, complying with national laws and regulations[192]. - The innovative production techniques have led to a significant reduction in raw material consumption and wastewater discharge, enhancing sustainability[78]. Governance and Management - The company strictly adheres to laws and regulations, ensuring a sound corporate governance structure and internal control systems[133]. - The board of directors consists of 9 members, with various specialized committees to support decision-making processes[134]. - The company maintains complete independence from its controlling shareholders in terms of business, personnel, assets, and finances[139]. - The company has established a comprehensive internal control system to manage risks and ensure operational efficiency[136]. - The company has a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and management team, ensuring effective decision-making and oversight[187]. Future Outlook - The company aims to become a leading provider of dyes, pesticides, and pharmaceutical intermediates in China, focusing on technological innovation and the development of new products and processes[119]. - In 2022, the company plans to continue emphasizing technological innovation, safety production, and green environmental protection, while consolidating its existing product advantages[120]. - The company will enhance its product quality and core technology, particularly in dye intermediates and pesticide/pharmaceutical intermediates, to strengthen its brand and market position[121]. - The company plans to adjust its organizational structure to improve decision-making and internal management as its business scales up[127]. - The company will consider strategic acquisitions or mergers with dye and pesticide production enterprises to enhance competitiveness and create new profit growth points[129].